Intellectual Property: Assessing and Interpreting the Importance of IP in Biotech Start-ups

The prevailing wisdom is that a strong intellectual property portfolio is an essential element of biotech startups and established companies. In some areas of technology, such as genetic diagnostics, the court decisions on patentability are in a state of utter chaos. How do startups and established companies operate in an environment of IP uncertainty? How important is IP?Join our distinguished panel to discuss this challenging and timely topic: Barry Myers, Professor and Director of Emerging Programs at Duke Translational Research Institute and Executive-in-Residence at Pappas Ventures, Jonathan Meltzer, VP of Corporate Development at LabCorp, and Jennifer Giordano-Coltart, Patent Attorney at Kilpatrick Townsend